Newbridge Acquisition Limited Unit
NBRGU
NASDAQ Capital Market10.18
USD
-0.07
- -
CIK
0001918414
ISIN
VGG6464L1105
CUSIP
G6464L110
Return %
Stock
S&P500
1Y
1.80
15.98
3Y
1.80
62.25
5Y
1.80
67.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Yongsheng Liu
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- Unit B 17/F Wan Chai Hong Kong
- IPO Date
- Jan 30, 2026
- CIK
- 0001918414
- Website
- truthsocial.com
- Similar Companies
- Business
- Newbridge Acquisition Limited Unit engages in effecting mergers, share exchanges, asset acquisitions, share purchases, recapitalizations, reorganizations or other similar business combinations. The company focuses on identifying and acquiring one or more healthcare-related businesses, with a primary emphasis on opportunities in Asian markets, including Greater China, and broader healthcare or healthcare-related companies with meaningful growth potential in the Asia-Pacific region; it aims to partner with targets that align with its strategic focus and value creation prospects. The company operates as a blank-check vehicle; it intends to consummate a business combination with a target having significant growth prospects and synergies with its healthcare concentration. The headquarters is in Hong Kong, China, and the company maintains a listing on the Nasdaq Capital Market under the ticker NBRGU. Newbridge Acquisition Limited Unit was founded in 2021 and pursues opportunities through a shell-structure SPAC model, leveraging strategic relationships with its sponsor and management to identify and secure a suitable transaction. The company’s ultimate parent is Newbridge Acquisition Limited, and it may pursue potential business combinations with entities either located in China/Hong Kong/Macau or with substantial ties to those markets, while remaining open to broader regional opportunities that fit its strategic criteria. The business model centers on enabling a fast-track route to a public-listed platform for a healthcare target, with ancillary services and potential ancillary fields including life sciences, medical devices, biotechnology, and digital health solutions, subject to the alignment of strategic fit and regulatory considerations. The latest major changes include the separate trading of the company’s Class A ordinary shares and rights within units following the IPO, reflecting an organizational and capital structure refinement to enhance liquidity and trading clarity; the company also reports ongoing IPO-related milestones and regulatory filings as part of its market-readiness and post-IPO execution plan. The description reflects core offerings, strategic posture, and current operational context as a finance-focused SPAC targeting healthcare opportunities in Asia and Greater China.
Newbridge Acquisition Limited Announces the Separate Trading of its Class A Ordinary Shares and Rights Commencing March 23, 2026
Newbridge Acquisition Limited Announces Closing of $57.5 Million Initial Public Offering